UNSPSC 51281632: Amikacin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H43N5O13.2H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6M33094FD, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->4))-n(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- but more generally known as amikacin sulfate, which bears US NIH Compound Identifier 37768. The base compound, Amikacin, most often comes in dihydrate, disulfate, hydrate, and sulfate forms.

UNSPSC 51281632 Amikacin sulfate is a Commodity code that does not reflect the scope of work actually being procured under it in recent state and local solicitations. The recent opportunities associated with this code — including naloxone procurement, therapeutic pharmacy initiatives, fire rescue medical supplies, and generic pharmaceuticals programs — do not involve amikacin sulfate or aminoglycoside antibiotics. The mismatch between the code's nominal scope and the actual goods being solicited suggests either a tagging error in the source data or that amikacin sulfate commands minimal direct procurement activity in state and local markets. State and local buyers who do source pharmaceuticals appear to use broader procurement vehicles — cooperative purchasing alliances for multi-source generics, emergency supply aggregations through county health departments, and fire service medical supply consolidations — rather than targeting individual antibiotic products by NDC or generic name.

Recent opportunities show activity across Florida (Seminole County naloxone procurement), Texas (HHS therapeutic pharmacy direct-to-manufacturer RFI), Florida (City of Tampa fire rescue medical supplies), and multi-state cooperative purchasing through Minnesota MMCAP serving participating jurisdictions including Oregon. The Tampa Fire Department Rescue Division procurement (IFB, due March 13, 2026, $700,000 estimated value) and the MMCAP generic pharmaceuticals RFP (due March 26, 2026) represent the most active recent solicitation types, both using cooperative or competitive bidding mechanisms rather than single-product vendor relationships. If amikacin sulfate is part of a buyer's formulary or supply list, it would surface within these broader pharmaceutical procurement vehicles rather than as a standalone solicitation.